Quick Answer
Protagonist Therapeutics, Inc reported Diluted EPS of $2.05 per share (loss) for fiscal year 2025.
Protagonist Therapeutics, Inc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.05 | -148.5% |
| 2024 | $4.23 | +404.3% |
| 2023 | -$1.39 | +46.5% |
| 2022 | -$2.60 | +4.1% |
| 2021 | -$2.71 | -41.1% |
| 2020 | -$1.92 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.62 | -14.8% | -12.7% |
| June 30, 2025 | -$0.55 | -10.0% | -189.5% |
| March 31, 2025 | -$0.19 | -105.8% | +64.8% |
| September 30, 2024 | -$0.54 | +6.9% | -8.0% |
| June 30, 2024 | -$0.50 | +26.5% | -115.3% |
| March 31, 2024 | $3.26 | +586.6% | +662.1% |
| September 30, 2023 | -$0.58 | +9.4% | +14.7% |
| June 30, 2023 | -$0.68 | +19.0% | -1.5% |
- Protagonist Therapeutics, Inc showed a decrease of -148.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Protagonist Therapeutics, Inc’s diluted eps has declined by 6.8% (from $1.92 per share (loss) to $2.05 per share (loss)).
- The most recent figure is from Protagonist Therapeutics, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: